GCM
MYGN icon

Glenview Capital Management’s Myriad Genetics MYGN Stock Holding History

Glenview Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,411,978
Closed -$24.4M – 52
2026
Q1 		$24.4M Buy
5,411,978
+824,571
+18% +$4.3M 0.61% 35
2025
Q4 		$28.2M Hold
4,587,407
– – 0.57% 40
2025
Q3 		$33.2M Hold
4,587,407
– – 0.74% 32
2025
Q2 		$24.4M Buy
4,587,407
+687,857
+18% +$4.06M 0.68% 29
2025
Q1 		$34.6M Sell
3,899,550
-257,774
-6% -$3.1M 0.85% 24
2024
Q4 		$57M Buy
4,157,324
+2,895,794
+230% +$53.4M 1.44% 23
2024
Q3 		$34.6M Sell
1,261,530
-2,486,902
-66% -$67.3M 0.67% 29
2024
Q2 		$91.7M Sell
3,748,432
-1,195,163
-24% -$26.2M 1.8% 17
2024
Q1 		$105M Sell
4,943,595
-340,387
-6% -$7.32M 1.84% 17
2023
Q4 		$101M Buy
5,283,982
+1,500,000
+40% +$25.9M 2.16% 15
2023
Q3 		$60.7M Buy
3,783,982
+39,094
+1% +$744K 1.37% 26
2023
Q2 		$86.8M Sell
3,744,888
-450,224
-11% -$9.83M 1.96% 16
2023
Q1 		$97.5M Buy
4,195,112
+1,097,344
+35% +$22.3M 2.14% 17
2022
Q4 		$44.9M Buy
3,097,768
+1,636,284
+112% +$30.5M 1% 27
2022
Q3 		$27.9M Sell
1,461,484
-235,307
-14% -$5.4M 0.7% 34
2022
Q2 		$30.8M Sell
1,696,791
-40,218
-2% -$835K 0.77% 30
2022
Q1 		$43.8M Buy
1,737,009
+57,262
+3% +$1.47M 0.89% 31
2021
Q4 		$46.4M Sell
1,679,747
-555,421
-25% -$16.1M 0.99% 32
2021
Q3 		$72.2M Sell
2,235,168
-240,912
-10% -$8M 1.31% 24
2021
Q2 		$75.7M Sell
2,476,080
-93,353
-4% -$2.7M 1.25% 28
2021
Q1 		$78.2M Sell
2,569,433
-1,113,258
-30% -$31.6M 1.33% 21
2020
Q4 		$72.8M Buy
3,682,691
+924,698
+34% +$14.9M 1.67% 17
2020
Q3 		$36M Buy
2,757,993
+947,266
+52% +$12M 1.13% 21
2020
Q2 		$20.5M Buy
1,810,727
+271,196
+18% +$3.85M 0.57% 34
2020
Q1 		$22M Sell
1,539,531
-1,905,264
-55% -$40.2M 0.6% 34
2019
Q4 		$93.8M Sell
3,444,795
-238,511
-6% -$6.56M 0.82% 31
2019
Q3 		$105M Buy
+3,683,306
New +$107M 1.11% 33

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Glenview Capital Management's MYGN Position: Q2 2026 in Review

Glenview Capital Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 5,411,978 shares — an estimated $24.4M sold.

Glenview Capital Management first reported a position in MYGN in Q3 2019 and held it in 27 quarters. The position peaked at $105M in Q3 2019. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Glenview Capital Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Glenview Capital Management sold 5,411,978 Myriad Genetics shares in Q2 2026, an estimated $24.4M.
  • Glenview Capital Management first reported a position in Myriad Genetics in Q3 2019 and held it in 27 quarters.
  • Glenview Capital Management's Myriad Genetics position peaked at $105M in Q3 2019.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Glenview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.